A report from iSpot.tv and Tubular Labs highlights that pharmaceutical brands are heavily concentrating ad spend on CTV and news programming, while telehealth brands are increasingly leveraging YouTube Shorts for high-volume engagement. The data indicates a shift in media strategy as pharma advertisers balance traditional linear reach with digital-first social video platforms.
The concentration of prescription drug advertising on streaming platforms indicates a strategic shift toward high-value, targeted digital environments that mirror traditional linear news reach. As immunology brands like Skyrizi and Tremfya outspend over-the-counter competitors by tens of millions, the streaming ecosystem is becoming a critical battleground for high-margin pharmaceutical products. This trend forces ad-supported platforms to balance medical content regulations with the lucrative demand for older, affluent viewer demographics. Watch for whether the 15.35% year-over-year growth in pharma impressions on Fox News translates into similar aggressive spending increases on right-leaning streaming news alternatives.
As US CTV ad spend continues to climb, pharmaceutical brands are increasingly leveraging the precision of programmatic advertising platforms to reach specific patient cohorts, a trend that programmatic competition intensifies as major players scale their operations. To navigate strict regulatory requirements, brands are also adopting Snapchat pharma ad format updates to ensure compliance while maintaining engagement.
Add StreamingMeme as a preferred source on Google to see more of our streaming news at the top of your Search results.
Add as preferred source